NCT05011669View on ClinicalTrials.gov

The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia

PHASE4CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

April 16, 2023

Study Completion Date

June 16, 2023

Conditions

Schizophrenia

Interventions

DRUG

Lurasidone

Oral administration with a meal or within 30 min after eating in the evening. The dosage could be adjusted from Day 8.

Trial Locations (1)

Unknown

Peking University Sixth Hospital, Beijing

All Listed Sponsors

lead

Sumitomo Pharma (Suzhou) Co., Ltd.

INDUSTRY

NCT05011669 - The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia | Biotech Hunter | Biotech Hunter